Introduction
The human microtubule associated protein tau is coded by the MAPT gene on chromosome with risk of neurodegeneration, we analysed the underlying MAPT genetic variation in PSP and CBD cases and showed that H1c, a sub-haplotype of the H1 clade, drives the association of the H1 haplotype -in other words, the H1c sub-haplotype contains the functional polymorphism that modulates risk [5, 6] . We also showed that the H1c sub-haplotype is associated with Alzheimer's disease (AD) [7] . We identified the H1c subhaplotype by a haplotype-tagging approach and one crucial SNP, rs242557 and its A-allele defines H1c. Interestingly, the association with PD is not driven by H1c i.e., it is limited to the H1-clade suggesting that the association with PD is driven solely by positional effects of the H1/H2 inversion whereas the association with PSP combines this effect with the influence of the cis-acting polymorphisms that define the H1 sub-haplotypes (for review, see [8] ).
Expression studies both in cell cultures and in post-mortem brain have shown H1/H2
allele-specific differences in transcription and splicing of MAPT. In general, the H1 haplotype has higher levels of transcription [4, 9] and production of 4R-tau mRNA due to increased inclusion of the alternatively spliced exon 10
and decreased levels of 2N-tau due to increased exclusion of exon 3 [10, 11] . We showed in vivo in post-mortem brain that the H1c haplotype is associated with increased MAPT transcription and inclusion of exon 10 [12] . In general, these studies strongly suggest that the basis of the risk due to the H1 haplotype is due to increased levels of tau protein with cis-modulation of [12] . The reporter assay was consistent with the view that rs242557 was a key part of promoter variability and a driver of the increased risk in PSP [12] . Moreover, in a recently completed genomewide association study (GWAS) Based on all this evidence, we surmised that the Region C containing rs242557 is an important regulatory motif for MAPT transcription and, cotranscriptional splice regulation and the aim of this study was to identify protein components of the transcription and splicing machinery that bind to this domain. Furthermore, identification of proteins with allele-specific binding behaviour would allow us investigate how rs242557 is able to exert such an influence.
experimental procedures

Nuclear protein fractionation
Nuclear extracts from SH-SY5Y and BE3-M17 neuroblastoma cell lines (ECACC) were obtained using the NE-PER® nuclear and cytoplasmic extraction kit (Pierce), according to manufacturer's instructions. These enabled stepwise separation of cytoplasmic and nuclear extracts. Before any extraction, fresh protease inhibitor pellets (Roche) were dissolved accordingly into the cytoplasmic and nuclear extraction reagents and kept on ice. The extraction process was scaled according to the weight of packed cells.
The nuclear extracts were aliquoted into pre-chilled reagent tubes and frozen on dry ice before storing at -80°C. The rs242557 alleles (A/G) are underlined.
After the nuclear extract was added, the reaction was allowed to equilibrate on ice Institute [19] . The SkyPainter, a tool used to map a user's list of genes or proteins of interest into reaction pathways has now been updated and replaced by the Pathway Analysis tool [20] . The overrepresentation analysis allows for clustering of the data into pathways, the higher the degree of clustering, the higher the probability of the proteins involved.
results
3.1 Subcellular fractionation of nuclear and cytoplasmic extracts proteins it was thus necessary to carry out the more sensitive ESI-QTOF/TOF sequencing of the digested peptide fragments. MS data generated from the runs were translated into protein hits using the manufacturer's software.
In total, we identified 43 proteins from the 22 protein bands we analysed, 37 of which were unique ( Table 1) Translational Neuroscience Figure 4 . SDS-PAGE gel of DNA-binding proteins purified using concatamerised probes of the region containing the H1c-A and H1b/H2-G allelotypes of rs242557 incubated with nuclear extracts of SH-SY5Y. Table 1 . List of protein hits from MS data generated. Proteins were positively identified within the protein bands excised using ProteinLynx Global Server (PLGS). It was possible for some of the 1-D protein bands to yield more than 1 protein identification. PLGS is Waters analytical platform which matched MS spectra against those generated from proteins in the Swissprot and Uniprot databases and generated the PLGS score. The higher the score, the higher the confidence in the match. and the efficiency of the trypsin digestion.
ProteinLynx Global Server (PLGS) (Waters) scoring used the selectivity of the exact mass we also used Reactome, to assess the reaction event(s) they are involved in according to a curated database of reaction pathways.
Each reaction event could consist of a few molecules to hundreds of molecules. Figure 9 illustrates the result of the analysis with all the interacting proteins and the coloured arrows indicated the pathways they are involved in. It is not surprising that they are involved in gene expression ( Figure 9 , Panel 1) and in mRNA synthesis in particular (Figure 9 ; Panels 2+3).
Using the Skypainter tool within Reactome, we can further display the pathways depending on the number of proteins implicated. In Panels 5-7, it is clear that the warmer (red) colour coding implicates most of the proteins within the mRNA splicing pathway. As it was a manually curated database, the strength of Reactome lies in its extensive database. Other, less represented pathways included the U12-dependent splicing pathway as well as the cleavage of mRNA at the 3' end and polyadenylation (Table 4) .
discussion
In [28, 29] . EDI is 270 bp long and contains an exon splice enhancer (ESE) that is recognized by the SR proteins SF2/ASF and 9G8. When transcription of the minigene is driven by the α-globin promoter, EDI inclusion levels in mature mRNA are about 10 times lower than when driven by the FN or CMV promoters [28, 29] . The importance of the effect of promoter identity on alternative splicing has also been demonstrated in several other genes, including the cystic fibrosis gene, CFTR [30] ; for references on other genes, see [31] ). A direct effect of promoter identity on alternative splicing of human MAPT exon 10 was shown by
Dawson and co-workers where they created transgenic (Tg) mice with a MAPT minigene bearing the N279K mutation, driven either by the MAPT core promoter or by the CMV promoter [32] . With the MAPT promoter, there was about a 1:1 ratio of 3R-tau/4R-tau mRNA in foetal brain and this converted to almost exclusively 4R-tau mRNA in the adult. However, with the CMV promoter, only 4R-tau mRNA was seen in both foetal and adult brain [32] .
Based on this, the identification several proteins involved in pre-mRNA splicing is credible in that they may form a complex either Table 3 . List of reactome events overrepresented by proteins of interest. Proteins of interest were matched to the reaction events they participated in. The events have been ordered according to the reaction pathway they are involved in. Refer to Figure 9 ; Panel (7). The warmer the colour, the higher the probability of the proteins involved in the reaction event. References supplementary data Figure S1 . Coverage of MS peptide data generated for 201.5 kDa band. 27 Blue -matched to a peptide, 14 red -matched to a partial peptide, 7 green -matched to a modified peptide, 7 yellow -matched to a partial modified peptide. Figure S2 . Coverage of MS peptide data generated for 109.4 kDa. 15 Blue -matched to a peptide, 9 red -matched to a partial peptide, 3 green -matched to a modified peptide, 3 yellow -matched to a partial modified peptide. Figure S3 . Coverage of MS peptide data generated for 103.5 kDa. 21 Blue -matched to a peptide, 10 red -matched to a partial peptide, 3 green -matched to a modified peptide, 5 yellow -matched to a partial modified peptide. Figure S4 . Coverage of MS peptide data generated for 95.4 kDa and fragmentation data for one of the peptides. Blue -matched to a peptide, red -matched to a partial peptide, green -matched to a modified peptide, yellow -matched to a partial modified peptide.
continued Figure S4 . Coverage of MS peptide data generated for 95.4 kDa and fragmentation data for one of the peptides. Blue -matched to a peptide, red -matched to a partial peptide, green -matched to a modified peptide, yellow -matched to a partial modified peptide. Figure S5 . Coverage of MS peptide data generated for 93 & 34.3 kDa and fragmentation data for one of the peptides. Blue -matched to a peptide, red -matched to a partial peptide, green -matched to a modified peptide, yellow -matched to a partial modified peptide. Figure S6 . Coverage of MS peptide data generated for 93 & 31.6 kDa and fragmentation data for two of the peptides. Blue -matched to a peptide, red -matched to a partial peptide, green -matched to a modified peptide, yellow -matched to a partial modified peptide. Figure S7 . Coverage of MS peptide data generated for 64 kDa. 7 Blue -matched to a peptide, 4 red -matched to a partial peptide, 1 green -matched to a modified peptide, 1 yellow -matched to a partial modified peptide. Figure S8 . Coverage of MS peptide data generated for 55 kDa. 6 Blue -matched to a peptide, 6 red -matched to a partial peptide, 6 green -matched to a modified peptide, 9 yellow -matched to a partial modified peptide. Figure S9 . Coverage of MS peptide data generated for 52.5 kDa and fragmentation data for one of the peptides. Blue -matched to a peptide, red -matched to a partial peptide, green -matched to a modified peptide, yellow -matched to a partial modified peptide. Figure S10 . Coverage of MS peptide data generated for 48.3 kDa. 5 Blue -matched to a peptide, 1 red -matched to a partial peptide, 4 green -matched to a modified peptide, 3 yellow -matched to a partial modified peptide. Figure S11 . Coverage of MS peptide data generated for 43.9 kDa. Blue -matched to a peptide, red -matched to a partial peptide, green -matched to a modified peptide, yellow -matched to a partial modified peptide.
continued Figure S11 . Coverage of MS peptide data generated for 43.9 kDa and fragmentation data for two of the peptides. Blue -matched to a peptide, red -matched to a partial peptide, green -matched to a modified peptide, yellow -matched to a partial modified peptide. Figure S15 . Coverage of MS peptide data generated for 30 kDa and fragmentation data for one of the peptides. Blue -matched to a peptide, red -matched to a partial peptide, green -matched to a modified peptide, yellow -matched to a partial modified peptide. Figure S16 . Coverage of MS peptide data generated for 28.2 kDa. 3 Blue -matched to a peptide, 5 red -matched to a partial peptide, 2 green -matched to a modified peptide, 3 yellow -matched to a partial modified peptide.
continued Figure S17 . Coverage of MS peptide data generated for 21.6 kDa and fragmentation data for one of the peptides. Blue -matched to a peptide, red -matched to a partial peptide, green -matched to a modified peptide, yellow -matched to a partial modified peptide. Figure S18 . Coverage of MS peptide data generated for 16 kDa and fragmentation data for two of the peptides. Blue -matched to a peptide, red -matched to a partial peptide, green -matched to a modified peptide, yellow -matched to a partial modified peptide.
continued Figure S18 . Coverage of MS peptide data generated for 16 kDa and fragmentation data for one of the peptides. Blue -matched to a peptide, red -matched to a partial peptide, green -matched to a modified peptide, yellow -matched to a partial modified peptide.
